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In recent years, there has been an increased interest in the development of alternative medicines for maintaining glucose homeostasis in diabetes, 
specifically by screening plant extracts as well as their isolated compounds for their ability to delay or prevent carbohydrate metabolism and absorption. 
The objective of present study was to undertake in-vitro and in-vivo studies to generate a stronger biochemical rationale for the management of post 
prandial hyperglycaemia (PPHG) with charantin. In this study, charantin (β-sitosteryl glucoside) was isolated from Momordica charantia Linn. by 
normal phase column chromatography and screened for the inhibition of key enzymes related to carbohydrate metabolism. Charantin showed mild α-
amylase (IC50 2.71± 0.21 mg/mL) and strong α-glucosidase (IC50 1.82±0.15 mg/mL) inhibitory activity. The positive in-vitro enzyme inhibition tests 
paved way for confirmatory in-vivo studies. The in-vivo studies demonstrated that charantin (20 mg/kg, b.w.) given orally significantly (P<0.01) reduced 
area under curve (AUC) in mice when challenged with oral administration of starch and sucrose separately. The reduction in AUC by charantin was 
comparable to that of acarbose (10 mg/kg, b.w., p.o.). These studies indicated the potential of charantin to prevent PPHG by inhibition of α-amylase 
and α-glucosidase enzymes. 
 




   
Diabetes mellitus is a chronic disorder of metabolism caused by 
an absolute or relative lack of insulin. The number of people in 
the world with diabetes has increased dramatically over the recent 
years1,2,3. The treatment of type 2 diabetes is complicated by 
several risk factors inherent to the disease. Elevated postprandial 
hyperglycemia (PPHG) is one of the risk factors4. One important 
factor to result in PPHG is the fast uptake of glucose in the 
intestine, in which α-amylase and α-glucosidase play important 
roles due to hydrolysis of polysaccharide and oligosaccharides. 
Inhibition of these enzymes has beneficial effects on glycemic 
control in diabetic patients5. Glucose homeostasis is also desirable 
to prevent diabetes related complications like cataract and 
nephropathy. Therefore, managing PPHG through the inhibition 
of α-amylase and α-glucosidase enzymes is an interesting strategy 
that excludes the involvement of insulin (pancreas). Inhibitors 
such as acarbose, voglibose and miglitol have been used clinically 
to control postprandial blood glucose levels in diabetes6. 
 
Momordica charantia Linn. (Cucurbitaceae) fruits are well 
known for their beneficial effects in diabetes that are often 
attributed to its bioactive component charantin7. It is commonly 
known as karela, bitter melon and bitter-gourd. Traditionally, it is 
considered as useful against diabetes and its related 
complications8-10. The fruits reduce elevated blood glucose 
level11, improve glucose tolerance12, decrease insulin resistance13, 
and increase the mass of β‑cells in pancreas14. Charantin, the main 
bioactive component, has been found to be more potent than oral 
hypoglycemic agent tolbutamide in alloxan‑induced diabetic 
rabbits15. Charantin is also reported to have antihyperglycemic 
and antifertility effects in rabbits16. There are no previous studies 
of evaluation of the role of charantin in glucose homeostasis. 
Hence, the present study aimed to establish the effectiveness of 
charantin in achieving glucose homeostasis via inhibition of 
carbohydrate metabolizing enzymes by in-vitro and in-vivo 
studies. 
 
MATERIALS AND METHODS  
 
Plant Material  
 
Fresh unripe fruits of M. charantia were collected from local 
vegetable market. A voucher specimen (PRL/JH/11/03) was 
deposited in Phyto‑pharmaceuticals Research Laboratory, School 





α-Amylase, α-glucosidase, p-nitrophenyl-α-D-glucopyranoside 
(PNPG) and 3,5-dinitrosalicylic acid (DNS) were purchased from 
SRL, Bangalore, India. Acarbose was obtained as gift sample 
from Medley Pharmaceutical Ltd. Jammu, India. All other 
solvents and chemicals were of analytical grade. 
 
Isolation of Charantin 
 
The fruits of bitter gourd were cleaned and sliced into small 




to a coarse powder using a grinder. About 1.5 kg of powder was 
extracted in Soxhlet apparatus for 72 hr with methanol (5 L). The 
extract was filtered and evaporated under reduced pressure at 50 
ºC in a rotary evaporator (Buchi, Switzerland). The total 
methanolic residue (280.37 g, 18.69 % w/w) was suspended in 
water (1 L) and then sequentially fractionated with hexane and 
ethyl acetate thrice (1 L, each). The ethyl acetate fraction (32 g; 
2.01 % w/w) was subjected to normal phase flash column 
chromatography using silica gel (60-120 mesh). The column was 
eluted with chloroform: methanol (50:50 v/v) and 15 fractions of 
250 ml each were collected. The fractions were subjected to TLC 
to check their homogeneity. Chromatographically identical 
fractions were combined and concentrated. Fractions 1-5 were 
pooled and yielded crude powder of charantin on keeping. 
Melting point, mass and other spectroscopic data were recorded 
for characterization and comparison. m.p.: 136-138°C.; UV λmax 
(MeOH): 205 nm; IR nmax (KBr):  3430 (OH), 1620 
(unsaturation), 1375 (C-O-C), 1121, 1055, 955 cm-1; +veEIMS 
m/z: 576 (C35H60O6); 1H and 13C NMR (CDCl3): data comparable. 
 
In-Vitro Enzyme Inhibition Assays 
 
The α-amylase inhibitory activity was carried out as per the 
method given by Ahamad et al.,1 with suitable modification. 
Briefly, 40 µL of charantin or acarbose (20 mM sodium 
phosphate buffer, pH 6.9 with 0.006 M sodium chloride) was 
premixed with 200 µL of α-amylase solution (1.0 U/mL in 
phosphate buffer pH 6.9), and incubated at 25 ºC for 30 min. After 
pre-incubation, 400 µL of 0.25 % starch solution in the phosphate 
buffer (pH 6.9) was added to each tube to start the reaction. The 
reaction was carried out at 37 ºC for 5 min and terminated by 
addition of 1.0 mL of the DNS reagent (1% 3,5-dinitrosalicylic 
acid and 12% sodium potassium tartrate in 0.4 M NaOH). The 
test tubes were then kept over a boiling water bath for 10 min and 
cooled to room temperature. The reaction mixture was then 
diluted by making up the volume to 10 ml by distilled water and 
absorbance (A) was measured at 540 nm. Control incubations 
representing 100% enzyme activity were conducted in a similar 
way by replacing test sample with buffer. For blank incubation 
enzyme and test solutions were replaced by buffer solution and 
absorbance recorded.  
 
The α-glucosidase inhibitory activity was assessed by the 
standard method as described by Ahamad et al.,1 with slight 
modifications. Briefly, a volume of 60 μL of sample solutions in 
DMSO charantin or acarbose in DMSO and 50 μL of 0.1 M 
phosphate buffer (pH 6.8) containing α-glucosidase solution (0.2 
U/mL) was incubated in 96 well plate at 37 ºC for 20 min. After 
pre-incubation, 50 μl of 5 mM p-nitrophenyl-α-D-
glucopyranoside (PNPG) solution in 0.1 M phosphate buffer (pH 
6.8) was added to each well and incubated at 37 ºC for another 20 
min. Then the reaction was stopped by adding 160 μl of 0.2 M 
Na2CO3 into each well, and absorbance (A) recorded at 405 nm 
by micro-plate reader and compared to a control which had 60 μL 
of buffer solution in place of the test sample. For blank incubation 
enzyme and test solutions were replaced by buffer solution and 
absorbance recorded.  




𝐴	𝑐𝑜𝑛𝑡𝑟𝑜𝑙 × 100 
 
where Acontrol, Atest, Abackground are defined as the absorbance of 
100% enzyme activity, test sample with the enzyme and test 
sample without the enzyme, respectively.  
 
The concentration of inhibitors required for inhibiting 50% of 
enzyme activity under assay conditions was defined as IC50 value. 
 
 




Wistar albino mice (30-40 g) were obtained from Central Animal 
Facility, Jamia Hamdard and maintained under controlled 
conditions of illumination (12h light/12h darkness) and 
temperature (20-25 ºC). They were housed under ideal laboratory 
conditions, maintained on standard pellet diet (Lipton rat feed 
Ltd., Pune, India) and water ad libitum throughout the 
experimental period. Animals were acclimatized to the conditions 
before start of the experiments. The experimental study was 
approved by the Institutional Animal Ethics Committee (IAEC) 
of Jamia Hamdard, New Delhi, India (Approval no. 
JH/CAHF/173/CPCSEA/2012/926).  
 
Oral Carbohydrate Challenge Tests 
 
Mice were fasted overnight for 12 h but had free access to water. 
The animals were randomly divided into seven groups consisting 
of six mice in each group (n = 6). Group I served as normal 
control which received 1 mL/kg b.w. vehicle (0.5% CMC in 
distilled water). For the oral starch tolerance test, Group II served 
as starch challenge control that received starch (3 g/kg, b.w.). 
Group III received acarbose as a standard drug (10 mg/kg, b.w.) 
while as group IV was administered charantin (20 mg/kg, b.w.). 
Treatment groups III and IV were fed starch (3 g/kg, b.w.) after 
20 min of treatment. For oral sucrose tolerance test, group V 
served as sucrose challenged control that received sucrose (4 
g/kg, b.w.). Treatment groups VI and VII received acarbose (10 
mg/kg, b.w.) and charantin (20 mg/kg, b.w.), respectively 
followed by sucrose (4 g/kg, b.w.) after 20 min of the treatment. 
Blood was withdrawn from the tail vein at 0, 30, 60, 90 and 120 
min after carbohydrate challenge. Blood glucose level (BGL) was 
measured using one-touch glucometer (my life Pura, 





Values are expressed as mean ± SD. Statistical significance was 
calculated by using one-way analysis of variance followed by 
Dunnett’s t-test. The values were considered significantly 
different when P<0.05. 
 
RESULTS   
 
Isolation of Charantin  
 
Charantin (β- Sitosteryl glucoside) was isolated by eluting the 
column with chloroform: methanol (50:50 v/v), as colourless 
crude powder from the fractions 1-5. The powder was 
recrystallized from methanol that gave colourless amorphous 
powder of charantin (215 mg, 0.028 % yield) with m.p. 136-
138°C. The structure of charantin (Figure 1) with a molecular 
formula C35H60O6 and molecular weight 576 amu, was confirmed 















Enzyme Inhibition by Charantin 
 
The charantin showed concentration dependant α-amylase 
inhibition that varied from 56.23±2.48 to 11.76±1.48 % for 5 to 
0.15 mg/mL, respectively.  Acarbose showed a concentration 
dependant response that varied from 81.33±2.31 to 31.29±4.35 % 
for 5 to 0.15 mg/mL, respectively. Figures 2 showed the 
percentage inhibition of α-amylase by charantin and acarbose. 
The IC50 values for charantin and acarbose were found as 




Figure 2: Inhibitory activity of acarbose and charantin against α-
amylase 
(Data were presented as mean of triplicate determinations ± SD) 
 
The results of in-vitro α-glucosidase inhibitory study are depicted 
in Figure 3. The charantin showed concentration dependant α-
glucosidase inhibition varying from 63.91±1.45 to 14.16±4.81 % 
for 5 to 0.15 mg/mL, respectively. Acarbose showed a 
concentration dependant response that varied from 76.82±4.48 to 
16.81±2.68 % for 5 to 0.15 mg/mL, respectively. The IC50 values 
for charantin and acarbose were found as 1.82±0.15 and 




Figure 3: Inhibitory activity of acarbose and charantin against α-
glucosidase 




In-vivo studies revealed that oral administration of starch (3 g/kg, 
b.w.) resulted significant (P<0.01) increase in blood glucose level 
in mice. Pre-treatment with charantin (20 mg/kg, b.w.) decreased 
BGL significantly (P<0.05) after 30 min of starch challenge to 
mice. Acarbose (10 mg/kg, b.w.) in mice also produced a 
significant (P<0.01) blood glucose lowering response after 30 
min (Table 1). The treatment with acarbose and charantin showed 
a significant (P<0.01) decrease in AUC in comparison to starch 
control group (Figure 4). Oral administration of sucrose (4 g/kg, 
b.w.) resulted significant (P<0.01) increase in BGL of mice. Pre-
treatment with charantin (20 mg/kg, b.w.) decreased BGL 
significantly (P<0.05) compared to sucrose challenge to mice. 
Acarbose (10 mg/kg, b.w.) also produced a significant (P<0.01) 
blood glucose lowering response after 30 min (Table 1). The 
treatment with acarbose and charantin showed a significant 
(P<0.01) decrease in AUC in comparison to sucrose control group 




Figure 4: AUC of carbohydrate challenged mice after treatment 
with acarbose and charantin 
 
Data were expressed as mean±SD, n=6, **P˂0.01, test groups vs 
respective carbohydrate controls; ##P˂0.01 carbohydrate controls 
vs normal control (NC). Treatment groups StC: starch control (3 
g/kg, b.w.); SuC: sucrose control (4 g/kg, b.w.); Acar: acarbose 




M. charantia has a long history of human use in traditional 
medicine throughout the world. Bitter-gourd fruits are well 
known for their beneficial effects in diabetes that are often 
attributed to its bioactive component charantin.9,15 The inhibitors 
of carbohydrate metabolizing enzymes such as acarbose 
significantly affect the activities of both these enzymes. The non-
specificity of action of these inhibitors results in flatulence that is 
due to an excessive inhibition of α-amylase leading to abnormal 
bacterial fermentation of undigested carbohydrates.6 Therefore, 
agents with comparatively more inhibitory activity against α-
glucosidase than against α-amylase will be helpful to overcome 
this challenge.1 Our results indicate that charantin showed 
stronger inhibition against α-glucosidase (IC50 1.82±0.15 mg/mL) 
than α-amylase (IC50 2.71±0.21 mg/mL). The inhibition for α-
glucosidase by charantin (IC50 1.85±0.18 mg/mL) was less than 
that of acarbose (IC50 1.45±0.09 mg/mL). In in-vivo experiments, 
pre-treatment with charantin restricted the blood glucose 
excursions and decreased both peak BGL and AUC in starch and 
sucrose challenged mice and the effect was comparable to 
acarbose. Charantin seemed to inhibit the carbohydrate 
metabolizing enzymes in the brush border of the small intestine. 
It successfully delayed the carbohydrate absorption. The 
retardation and delay of carbohydrate metabolism and absorption 
by charantin offers a prospective therapeutic approach for the 
management of PPHG for pre-diabetics or who have blood 
glucose levels only slightly above the level considered serious for 










Table 1: Effect on blood glucose level of charantin and acarbose in carbohydrate challenged mice 
 
Group Blood glucose level (mg/dl) 
0 min 30 min 60 min 90 min 120 min 
Starch tolerance test 
NC 101.4±1.20 100.8±1.07 102±1.14 103±0.45 102±1.09 
StC 100.6±1.54 170.4±1.86## 161.8±1.93## 154.6±1.07## 146±1.64## 
Acar 98.4±0.24 130.8±2.27** 115.4±1.33** 109.8±0.73** 106.4±0.75** 
Chara 96.8±1.65 151.4±1.96* 141±3.36** 134.4±2.6** 122.6±1.4** 
Sucrose tolerance test 
SuC 102.8±0.97 180.6±2.25## 175.2±2.08## 160.6±2.76## 148.8±1.07## 
Acar 102.2±1.2 143.8±1.66** 139.8±1.16** 128.8±1.56** 115.6±0.68** 
Chara 100.6±0.75 172.4±2.98ns 156.8±3.34** 136.2±1.66** 127.2±0.80** 
 
Data were expressed as mean±SD, n=6, *P˂0.05, **P˂0.01, test 
groups vs respective carbohydrate controls; ##P˂0.01 
carbohydrate controls vs normal control (NC). Treatment groups 
StC: starch control (3 g/kg, b.w.); SuC: sucrose control (4 g/kg, 





The present study demonstrated the role of charantin in inhibiting 
α-amylase and α-glucosidase enzymes. Charantin was effective 
in the achieving stricter glycemic control in carbohydrate 
challenged mice through the inhibition of carbohydrate 
metabolizing enzymes. The present study proves the traditional 
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